Thyroiditis While Receiving Programmed Death Ligand 1 (PD-L1) Inhibitor Therapy for Nonthyroid Cancers Is Associated with Improved Overall Survival-Reference-Cited by-同舟云学术

Thyroiditis While Receiving Programmed Death Ligand 1 (PD-L1) Inhibitor Therapy for Nonthyroid Cancers Is Associated with Improved Overall Survival

Published:2020-02-01 Issue:2 Volume:32 Page:65-68
ISSN:2329-9711
Container-title:Clinical Thyroidology
language:en
Short-container-title:Clinical Thyroidology

Author:

Angell Trevor E.¹

Affiliation:

1. Division of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, U.S.A.

Publisher

Mary Ann Liebert Inc

Subject

General Engineering

Link

https://www.liebertpub.com/doi/pdf/10.1089/ct.2020%3B32.65-68

Reference8 articles.

1. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

2. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

3. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

4. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

5. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis;Cancers;2023-12-11

2. Endocrine complications of new anticancer therapies;Postępy Higieny i Medycyny Doświadczalnej;2021-03-18